title: Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma.
abstract: The aim of this retrospective study was to assess the efficacy and tolerance of intravenous rituximab in multifocal primary cutaneous follicle centre lymphomas (PCFCL). Eleven patients with a multifocal PCFCL were treated with rituximab (MabThera(®)) administrated intravenously. After four infusions, an objective response was observed in 90% of patients, and one month after all the infusions (median of 6 infusions) all the patients had an objective response and complete remission was obtained in 7 of 11 patients (64%). Follow-up ranged from 9 to 65 months (median: 30 months). Local disease recurrence was observed in five patients. The median progression-free survival time after the end of treatment was 23.6 months. This study is the largest series of patients with multifocal primary PCFCL treated with intravenous rituximab. This therapy is a safe and effective treatment and could represent an excellent alternative treatment to radiotherapy.
authors.affiliation: Skin Cancer Unit, Nantes University Hospital, INSERM, Nantes, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Quéreux
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.forename: Jean Michel
authors.initials: JM
authors.lastname: Nguyen
authors.forename: Anne-Chantal
authors.initials: AC
authors.lastname: Knol
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D000069283:Rituximab; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab